Published on 08/12/2025

Setting AET and DBT: Practical Calculations That Survive Audit

In today’s highly regulated pharmaceutical environment, ensuring the safety and efficacy of products is paramount. A critical aspect of this is the evaluation of materials, particularly in terms of extractables and leachables (E&L). Understanding how to set the Analytical Evaluation Threshold (AET) and Dose-Based Threshold (DBT) is vital for compliance with regulatory expectations, including those from the FDA, EMA, and MHRA. This guide provides a step-by-step approach to determining AET and DBT, ensuring your processes are audit-ready.

Understanding Extractables and Leachables (E&L)

Extractables and leachables are substances that can potentially migrate into drug products from packaging and container closure systems. Evaluating these substances is crucial to ensure they do not pose a risk to the patient. Regulations surrounding E&L require that pharmaceutical companies conduct thorough risk assessments to anticipate and mitigate any potential issues associated with these materials.

Extractables are the compounds that can be extracted from materials under extreme conditions, such as temperature or solvent exposure. Leachables, on the other hand, are the compounds that migrate into the product under actual storage and usage conditions. This distinction is critical when assessing risks and establishing thresholds.

The regulatory expectations surrounding E&L can be found in various guidelines, such as the FDA guidance on container closure systems, and the EMA guidelines for veterinary and human use. Additionally, the Pharmacopoeial Convention provides guidelines via USP, especially in terms of container closure integrity (CCI) testing protocols.

Overview of AET and DBT

The Analytical Evaluation Threshold (AET) is defined as the limit of E&L that must be detected in an analytical test in order to consider its impact on product safety and quality. Conversely, the Dose-Based Threshold (DBT) provides a safety threshold based on the estimated dose of the drug product being evaluated. Establishing these thresholds is crucial when conducting risk assessments and ensuring compliance with regulations.

The AET is set based on toxicological safety criteria and can vary widely among different substances. Establishing DBT requires a detailed analysis of both the drug formulation and its delivery method, understanding how the leachables may interact with the drug product across the intended route of administration.

The two sets of thresholds serve different purposes, and understanding both helps ensure comprehensive risk assessment and validation protocols. By establishing clear AET and DBT calculations, pharmaceutical manufacturers can significantly improve their compliance posture.

Step-by-Step Process to Establish AET

Establishing the Analytical Evaluation Threshold (AET) requires a systematic approach. Below is a step-by-step process to help pharmaceutical professionals determine AET accurately.

Step 1: Identify Relevant E&L Compounds

Start by compiling a list of potential extractables and leachables based on the materials used in your packaging system. This should involve a thorough literature review and consideration of previously published studies relevant to similar products.

Step 2: Determine Toxicological Profiles

Once you have identified the compounds, determine their toxicological profiles. Utilize resources such as the REACH database, the FDA’s toxicology principles, and other reputable sources to assess the safety thresholds of each identified compound.

Step 3: Calculate AET Values

The calculation of AET typically relies on the following formula:

• AET = Safety Threshold / Safety Factor

Where the safety threshold is based on allowable daily exposure or toxicological data, and the safety factor is often defined as 100 for chronic exposure. Ensure that the calculations are documented thoroughly for compliance purposes.

Step 4: Validate through Analytical Testing

Following AET determination, the next step is to validate the established thresholds through analytical testing. Employ standardized methods such as LC-MS/MS or GC-MS to ensure accuracy in detecting any relevant E&L compounds.

Establishing DBT: A Practical Guide

Setting the Dose-Based Threshold (DBT) involves another layer of intricacy. Follow this structured approach to establish DBT appropriately.

Step 1: Gather Formulation Data

Begin by collecting data regarding the formulation of your drug product, including dosage strengths, routes of administration, and concentration of active pharmaceutical ingredients (APIs). Understanding the product’s pharmacokinetics and pharmacodynamics is equally important.

Step 2: Assess Patient Population

Evaluate the patient population your product targets, including age, weight, and potential health conditions. Different groups may have differing tolerances to specific chemicals based on their biological diversity.

Step 3: Execute DBT Calculations

The calculation of DBT usually follows this formula:

• DBT = (Maximum Daily Dose x Acceptable Daily Exposure) / Total Volume of Container

Similarly to AET calculations, accuracy in this stage is crucial to ensure both safety and regulatory compliance.

Step 4: Monitor and Review

After determining the DBT, ongoing monitoring is essential. Data should be routinely reviewed and assessed against emerging scientific evidence and evolving regulatory guidelines. Keeping abreast of changes in industry best practices can be critical for maintaining compliance.

Compliance with Regulations: Best Practices

Compliance with regulatory bodies such as the FDA and EMA requires rigorous adherence to established guidelines for E&L. Integrating these practices into your AET and DBT calculations ensures that your assessments are both defensible and robust.

Understanding the guidelines from EU GMP Annex 1 and the PQRI guideline will aid in your approach. Follow these best practices:

• Document everything: Maintain thorough documentation at every stage, from identification of compounds to calculation methodologies.
• Utilize existing literature: Leverage previously published studies as a benchmark for known thresholds.
• Conduct regular reviews: Regularly reassess both AET and DBT in light of new data and regulatory updates.

Integrated E&L Risk Management

Implementing a comprehensive E&L risk assessment requires collaboration across various departments, including Quality Assurance (QA) and Quality Control (QC). Integrating different aspects of compliance into a cohesive risk management framework is essential.

Promote communication between teams to share insights on risk factors associated with E&L, and conduct cross-department training to foster a culture of compliance. Regular workshops and meetings can bridge gaps and align goals related to E&L assessments.

Your organization should also consider using risk assessment tools to streamline evaluations and documentation. Software solutions can aid in tracking E&L risk assessments and ensuring compliance with regulatory standards, thus simplifying the audit process.

Conclusion

Setting Analytical Evaluation Thresholds (AET) and Dose-Based Thresholds (DBT) is essential for ensuring compliance with E&L regulations. Following the structured approaches outlined in this article will facilitate a systematic determination of these values while maintaining readiness for audits from regulatory bodies such as the FDA, EMA, and MHRA.

By investing in robust processes for E&L assessment, pharmaceutical manufacturers can enhance their safety profiles, mitigate risks associated with extractables and leachables, and ultimately contribute to the protection of patient health.

For continuous updates and detailed information refer to official guidelines from relevant regulatory authorities and industry documents. Engaging with these resources provides valuable insights that can influence your organization’s compliance strategy positively.